NASDAQ:DARE - Dare Bioscience Stock Price, News & Analysis

$0.84
-0.04 (-4.57 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$0.7860
Now: $0.8350
$0.88
50-Day Range
$0.74
MA: $0.79
$0.86
52-Week Range
$0.60
Now: $0.8350
$3.25
Volume7,969 shs
Average Volume552,436 shs
Market Capitalization$13.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-16,740,000.00

Miscellaneous

Employees5
Market Cap$13.93 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.


Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) announced its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.09. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

2 Wall Street analysts have issued 1 year target prices for Dare Bioscience's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Dare Bioscience's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 259.3% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

What is the consensus analysts' recommendation for Dare Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Has Dare Bioscience been receiving favorable news coverage?

News coverage about DARE stock has been trending negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dare Bioscience earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Dare Bioscience.

Who are some of Dare Bioscience's key competitors?

What other stocks do shareholders of Dare Bioscience own?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
  • Mr. Mark Walters, VP of Operations (Age 64)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)
  • Dr. David Friend, Chief Scientific Officer

Who are Dare Bioscience's major shareholders?

Dare Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.26%). View Institutional Ownership Trends for Dare Bioscience.

Which major investors are buying Dare Bioscience stock?

DARE stock was acquired by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. View Insider Buying and Selling for Dare Bioscience.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.8350.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $13.93 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.View Additional Information About Dare Bioscience.

What is Dare Bioscience's official website?

The official website for Dare Bioscience is http://www.darebioscience.com/.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel